Fortis Healthcare Gains 2.18%: 5 Key Factors Driving the Week’s Momentum

8 June: Bullish Derivatives Activity Spurs Price Gains

Fortis Healthcare began the week with a strong 1.93% gain to close at Rs.987.95, despite the Sensex falling 1.33% that day. The stock emerged as the most actively traded in call options, with 5,516 contracts at the Rs.1,000 strike expiring 30 June, generating a turnover of approximately Rs.1238.44 lakhs. Open interest surged to 20,476 contracts, a 22.74% increase, signalling heightened bullish sentiment among traders.

The stock briefly surpassed the psychologically significant Rs.1,000 level intraday, touching Rs.1,003.75, reflecting strong technical momentum. This surge in derivatives activity coincided with Fortis outperforming its hospital sector peers by over 1.6%, underscoring its appeal amid sector volatility. However, delivery volumes declined by 15.51%, suggesting that short-term traders and option market participants primarily drove the rally rather than long-term holders.

8 June: Valuation Metrics Shift to Very Expensive

Alongside price gains, Fortis Healthcare’s valuation profile shifted markedly. The price-to-earnings ratio rose to 69.13, placing the stock in the “very expensive” category, a notable increase from its previous “expensive” rating. The price-to-book value climbed to 7.39, while enterprise value to EBITDA and EBIT ratios stood at 36.49 and 46.52 respectively, significantly higher than key peers such as Narayana Hrudaya and Global Health.

Despite these elevated multiples, Fortis’s return on capital employed (12.77%) and return on equity (10.70%) remained respectable but did not fully justify the premium valuation. The company’s modest dividend yield of 0.10% further highlighted limited income returns for investors. This valuation shift coincided with a downgrade in the MarketsMOJO mojo grade to Sell on 1 June, reflecting caution amid stretched fundamentals.

9 June: MarketsMOJO Upgrades Rating to Hold on Technical and Valuation Shifts

On 9 June, MarketsMOJO upgraded Fortis Healthcare’s mojo grade from Sell to Hold, reflecting a nuanced reassessment of the stock’s technical outlook and valuation. The upgrade was driven primarily by improved technical indicators, including a bullish weekly MACD, bullish Bollinger Bands on weekly and monthly charts, and a mildly bullish Dow Theory assessment. The stock’s price stabilised at Rs.987.95, with intraday highs reaching Rs.1,004.35.

Despite the upgrade, valuation metrics remained stretched, with the P/E ratio rising to 70.46 and EV/EBITDA at 37.17. The company’s financial trend showed flat quarterly earnings, with interest expenses rising 34.35% to Rs.244.90 crores for the nine months ended March 2026. However, operating profit growth remained robust over the longer term, with a compound annual growth rate of 70.40%. Institutional ownership stood at a strong 57.17%, providing stability amid cautious investor sentiment.

9 June: Technical Momentum Shifts Signal Mildly Bullish Outlook

Technical momentum continued to improve on 9 June, with Fortis Healthcare’s stock closing at Rs.987.95, up 1.93% from the previous close. The stock’s intraday range of Rs.952.30 to Rs.1,004.35 approached its 52-week high of Rs.1,105.00, signalling a robust recovery trajectory. Key technical indicators supported a mildly bullish outlook, including a bullish weekly MACD and Bollinger Bands, while the monthly MACD remained mildly bearish, suggesting some caution over the longer term.

The Relative Strength Index (RSI) remained neutral, indicating the stock was neither overbought nor oversold, allowing room for further appreciation. Dow Theory assessments and the Know Sure Thing (KST) indicator also pointed to early signs of an upward trend, though daily moving averages showed mild bearishness, hinting at possible short-term consolidation or resistance.

12 June: Week Closes with Modest Gains Amid Strong Sensex Rally

Fortis Healthcare closed the week at Rs.990.40 on 12 June, a 0.15% gain on the day and a 2.18% increase from the previous Friday’s close. This outpaced the Sensex’s 0.57% weekly rise, which was bolstered by a strong 2.20% gain on the same day. Volume surged to 237,571 shares, matching the highest volume day of the week, indicating renewed investor interest as the broader market rallied.

The stock’s steady performance amid a volatile week reflects a balance between bullish technical momentum and cautious fundamental considerations. The closing price near the week’s high suggests resilience and potential for further consolidation above key support levels.

Key Takeaways

Positive Signals: Fortis Healthcare’s sustained outperformance relative to the Sensex and hospital sector peers highlights strong technical momentum and investor interest. The surge in call option activity and open interest reflects bullish sentiment targeting the near-term Rs.1,000 strike price. The MarketsMOJO upgrade to Hold signals improving fundamentals and technical outlook, supported by robust long-term returns and institutional ownership.

Cautionary Notes: Elevated valuation multiples, including a P/E above 70 and a very expensive rating, suggest limited near-term upside without further fundamental improvements. Flat quarterly earnings and rising interest expenses temper enthusiasm. Declining delivery volumes indicate that short-term traders may be driving price action more than long-term holders, raising the risk of volatility near expiry dates.

Conclusion

Fortis Healthcare’s week was characterised by a blend of bullish technical momentum and cautious fundamental signals. The stock’s 2.18% weekly gain, supported by strong derivatives activity and a MarketsMOJO rating upgrade, underscores growing investor confidence in its near-term prospects. However, the very expensive valuation and flat recent earnings counsel prudence. Market participants should monitor upcoming quarterly results and price action around key technical levels, particularly the Rs.1,000 strike, to gauge sustainability of the current trend.

Only Rs. 9,999 - Get MojoOne + Stock of the Week for 1 Year Start at 33% Off →